Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation

Description

This research study aims to compare whether Phenylephrine 2.5% ophthalmic eye drop solution can serve as a better indicator of the effect of a drooping upper eyelid (ptosis) by covering part of the upper portion of the field of vision as compared to traditional use of tape to lift up the upper eyelid in the evaluation of patients for surgical upper eyelid repair.

Conditions

Ptosis, Eyelid

Talk to us

Study Overview

On this page

Study Details

Study overview

This research study aims to compare whether Phenylephrine 2.5% ophthalmic eye drop solution can serve as a better indicator of the effect of a drooping upper eyelid (ptosis) by covering part of the upper portion of the field of vision as compared to traditional use of tape to lift up the upper eyelid in the evaluation of patients for surgical upper eyelid repair.

Phenylephrine Versus Upper Eyelid Taping For Muller's Muscle Conjunctival Resection Evaluation

Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation

Condition
Ptosis, Eyelid
Intervention / Treatment

-

Contacts and Locations

Miami

University of Miami Bascom Palmer Eye Institute, Miami, Florida, United States, 33136

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Individuals diagnosed with ptosis undergoing conjunctival Muller's muscle resection evaluation.
  • * Individuals who can tolerate and have no hypersensitivity to phenylephrine 2.5% ophthalmic solution.
  • * Individuals who can tolerate eye-drop medications.
  • * Individuals who are physically able to take a tangent screen visual field test.
  • * Age: Adults who can comprehend the instructions and procedures (18-90 years old).
  • * This study will not include participants who refuse to consent.
  • * This study will not include participants who are too tired or unable to take a tangent screen visual field test (see Risk to Subjects).
  • * This study will not include individuals who may not be able to tolerate phenylephrine 2.5% ophthalmic solution.
  • * Specifically, those with a past medical history of bradycardia, hypotension, autonomic dysfunction, or severe cardiovascular disease
  • * This study will not include individuals who consume drugs contraindicated in phenylephrine use: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates), Iobenguane Radiopharmaceutical Products, Kratom, Lisuride, Monoamine Oxidase Inhibitors

Ages Eligible for Study

18 Years to 90 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Miami,

Sara T Wester, MD, PRINCIPAL_INVESTIGATOR, University of Miami

Study Record Dates

2025-03-01